{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:50:05Z","timestamp":1776487805477,"version":"3.51.2"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41409-020-01145-1","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T20:03:52Z","timestamp":1606161832000},"page":"1031-1037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease\u2014a single center case series"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-2135","authenticated-orcid":false,"given":"Efrat","family":"Luttwak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hagin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chava","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-0707","authenticated-orcid":false,"given":"Ofir","family":"Wolach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilad","family":"Itchaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odelia","family":"Amit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Bar-On","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Freund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigi","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinat","family":"Eshel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-444X","authenticated-orcid":false,"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Ram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"1145_CR1","doi-asserted-by":"publisher","first-page":"15088","DOI":"10.1038\/nrdp.2015.88.","volume":"2","author":"VR Dharnidharka","year":"2016","unstructured":"Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nat Rev Dis Prim. 2016;2:15088 https:\/\/doi.org\/10.1038\/nrdp.2015.88.","journal-title":"Nat Rev Dis Prim"},{"key":"1145_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/bjh.15263.","volume":"182","author":"CB DeStefano","year":"2018","unstructured":"DeStefano CB, Desai SH, Shenoy AG, Catlett JP. Management of post-transplant lymphoproliferative disorders. Br J Haematol. 2018;182:330\u201343. https:\/\/doi.org\/10.1111\/bjh.15263.","journal-title":"Br J Haematol"},{"key":"1145_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bjh.16304.","volume":"189","author":"MD Jain","year":"2020","unstructured":"Jain MD, Lam R, Liu Z, Stubbins RJ, Kahlon A, Kansara R, et al. Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder. Br J Haematol. 2020;189:97\u2013105. https:\/\/doi.org\/10.1111\/bjh.16304.","journal-title":"Br J Haematol"},{"key":"1145_CR4","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872.","volume":"126","author":"D Dierickx","year":"2015","unstructured":"Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood. 2015;126:2274\u201383. https:\/\/doi.org\/10.1182\/blood-2015-05-615872.","journal-title":"Blood"},{"key":"1145_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5500\/wjt.v10.i2.29.","volume":"10","author":"F Abbas","year":"2020","unstructured":"Abbas F, El Kossi M, Shaheen IS, Sharma A, Halawa A. Post-transplantation lymphoproliferative disorders: current concepts and future therapeutic approaches. World J Transplant. 2020;10:29\u201346. https:\/\/doi.org\/10.5500\/wjt.v10.i2.29.","journal-title":"World J Transplant"},{"key":"1145_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMcibr1415117","volume":"372","author":"VR Dharnidharka","year":"2015","unstructured":"Dharnidharka VR, Mohanakumar T. New approaches to treating B-cell cancers induced by Epstein-Barr virus. N. Engl J Med 2015;372:569\u201371. https:\/\/doi.org\/10.1056\/NEJMcibr1415117","journal-title":"N. Engl J Med"},{"key":"1145_CR7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3324\/haematol.2010.023689.","volume":"95","author":"A Merlo","year":"2010","unstructured":"Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, et al. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica. 2010;95:1769\u201377. https:\/\/doi.org\/10.3324\/haematol.2010.023689.","journal-title":"Haematologica"},{"key":"1145_CR8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/jco.2015.64.5929.","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 CHimeric Antigen Receptor Induce Remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112\u201321. https:\/\/doi.org\/10.1200\/jco.2015.64.5929.","journal-title":"J Clin Oncol"},{"key":"1145_CR9","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741.","volume":"122","author":"CR Cruz","year":"2013","unstructured":"Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122:2965\u201373. https:\/\/doi.org\/10.1182\/blood-2013-06-506741.","journal-title":"Blood"},{"key":"1145_CR10","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41375-019-0476-y","volume":"33","author":"T Jain","year":"2019","unstructured":"Jain T, Sauter CS, Shah GL, Maloy MA, Chan J, Scordo M, et al. Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/ refractory B cell non-Hodgkin lymphoma. Leukemia. 2019;33:2540\u20134.","journal-title":"Leukemia"},{"key":"1145_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791.","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367. https:\/\/doi.org\/10.1002\/ajh.25791.","journal-title":"Am J Hematol"},{"key":"1145_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758.","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1145_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1172\/jci121127.","volume":"130","author":"S Prockop","year":"2020","unstructured":"Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020;130:733\u201347. https:\/\/doi.org\/10.1172\/jci121127.","journal-title":"J Clin Invest"},{"key":"1145_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-017-0405-3.","volume":"10","author":"J Liu","year":"2017","unstructured":"Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017;10:35 https:\/\/doi.org\/10.1186\/s13045-017-0405-3.","journal-title":"J Hematol Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01145-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:17:07Z","timestamp":1684617427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01145-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01145-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"21 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}